---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-051347"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:38:39.073221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma appoints Dr. Uttam Patil as CEO after Dr. Howard Doong resigns

## Summary
- Dr. Howard Doong resigned as CEO effective June 21, 2023; no disagreement with Company operations.
- Board appointed Dr. Uttam Yashwant Patil as CEO and President effective June 23, 2023.
- Dr. Patil also serves as COO and Scientific Officer of subsidiary BioKey since May 2023.
- New employment agreement provides one-year term, salary paid in stock options, and severance in stock shares.
- He holds a Ph.D. in Chemistry from National Tsing Hua University and previously served as post-doctoral fellow at NTNU.

## SEC filing metadata
- accession: 0001213900-23-051347
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/ea180822-8k_abvcbiopharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-051347
- JSON: https://secwatch.observer/filing/0001213900-23-051347.json
- Plain text: https://secwatch.observer/filing/0001213900-23-051347.txt

## Key facts
- Executive change
  Dr. Uttam Yashwant Patil was appointed as Chief Executive Officer at ABVC BIOPHARMA, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm
- Executive change
  Dr. Howard Doong resigned as Chief Executive Officer at ABVC BIOPHARMA, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.